NIMBUS APOLLO
Previously a sub-organization of Nimbus Therapeutics, the Nimbus Apollo program includes the lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases. NDI-010976 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in February 2016 and Phase 1 data for the compound will be presented next month during an oral session at The International Liver Congress 2016, the annual meeting of the European Association for the Study of the Liver (EASL).
NIMBUS APOLLO
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2010-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.nimbustx.com
Total Employee:
11+
Status:
Active
Contact:
857-999-2009
Email Addresses:
[email protected]
Total Funding:
43 M USD
Similar Organizations
Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
Investors List
Lightstone Ventures
Lightstone Ventures investment in Series B - Nimbus Apollo
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Nimbus Apollo
Official Site Inspections
http://www.nimbustx.com
- Host name: 145.205.196.104.bc.googleusercontent.com
- IP address: 104.196.205.145
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
